Thrill Pharma GW 501516

GW 501516

GW-501516, commonly referred to as Cardarine, is a PPAR-delta agonist that was originally developed by GlaxoSmithKline for the treatment of metabolic and cardiovascular disorders. Its primary mechanism involves activation of PPAR-delta in skeletal muscle, which upregulates genes involved in fatty acid oxidation, mitochondrial biogenesis, and oxidative metabolism — producing dramatic improvements in endurance capacity and fat burning.

In performance settings, Cardarine is renowned for producing remarkable increases in aerobic endurance, with users and research models consistently demonstrating the ability to run longer, sustain higher intensities, and recover faster between aerobic bouts. It also accelerates fat oxidation significantly, making it an extremely effective fat loss agent during cutting phases.

Cardarine does not suppress testosterone production or require post-cycle therapy, as it operates entirely outside the androgen receptor system. It is commonly stacked with SARMs in both cutting and recomposition protocols to add endurance and fat-burning support without additional hormonal suppression.

Disclaimer: Above mentioned information is for educational and reference purposes only. Consult a registered healthcare professional for a proper course of medication. These statements have not been evaluated by the Food and Drug Administration. This product shall only be available on a prescription from a registered healthcare professional.

Frequently Asked Questions